Novel Peptides for Preventing or Treating Bone Diseases and Use Thereof

Abstract

The present disclosure relates to a novel peptide for preventing or treating bone diseases. Further, the present disclosure relates to a polynucleotide encoding the peptide, a vector including the polynucleotide, a host cell transformed by the vector, and a method for producing the peptide by using the host cell. Furthermore, the present disclosure relates to a composition for preventing or treating bone diseases, including the novel peptide. The novel peptide according to the present disclosure induces mobilization of hematopoietic stem cells to blood and causes a decrease in the number of osteoclasts, and, thus, decreases bone erosion caused by osteoclasts, thereby suppressing progress of an osteoporotic lesion. Further, the novel peptide is safe since it does not cause rejection in the body. Furthermore, since the novel peptide is formed of 16 short amino acids, a low dose of the peptide can relieve symptoms of osteoporosis.

1 . A peptide for preventing or treating a bone disease, the peptide consisting of the amino acid sequence of SEQ ID NO: 1. 
     
     
         2 . The peptide of  claim 1 , wherein the bone disease is any one selected from the group consisting of osteoporosis, osteomalacia, rickets, fibrous ostitis, an adynamic bone disease, and a metabolic bone disease. 
     
     
         3 . The peptide of  claim 1 , wherein the peptide decreases an expression level of an adhesion factor for a bone marrow hematopoietic stem cell and mobilizes the bone marrow hematopoietic stem cell in bone marrow to a bloodstream. 
     
     
         4 . The peptide of  claim 1 , wherein the peptide decreases osteoclasts in the bone marrow. 
     
     
         5 . A polynucleotide encoding a peptide of  claim 1 . 
     
     
         6 . A method for treating a target with a bone disease, comprising:
 administering a peptide having an amino acid sequence of SEQ ID NO: 1 in a therapeutically effective amount to a target in need of help.   
     
     
         7 . The method of  claim 6 , wherein the bone disease is any one selected from the group consisting of osteoporosis, osteomalacia, rickets, fibrous ostitis, an adynamic bone disease, and a metabolic bone disease. 
     
     
         8 . The method of  claim 6 , wherein the peptide decreases an expression level of an adhesion factor for a bone marrow hematopoietic stem cell and mobilizes the bone marrow hematopoietic stem cell in bone marrow to a bloodstream. 
     
     
         9 . The method of  claim 6 , wherein the peptide decreases osteoclasts in the bone marrow.